ScreenerHero

ATOSAtossa Therapeutics, Inc.

NAS · US · Healthcare · Biotechnology · atossatherapeutics.com
2.540USD-3.79%Mkt Cap: 25.35M $P/E: —

Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines in areas of significant unmet medical need in oncology in the United States. Its lead drug candidate is oral (Z)-endoxifen, a sele…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$138.82BUSDP/E 31.9
REGN
Regeneron Pharmaceuticals, Inc.
$85.87BUSDP/E 20.5
ARGX
ARGENX SE
$61.34BUSDP/E 39.8
ARGX
argenx SE
$65.05BUSDP/E 39.6
MRNA
Moderna, Inc.
$57.94BUSD
UCB
UCB SA
$45.95BUSDP/E 19.6
RVMD
Revolution Medicines, Inc.
$44.89BUSD
ONC
BeOne Medicines AG
$42.36BUSDP/E 67.2
RPRX
Royalty Pharma Plc Class A
$35.43BUSDP/E 32.6
ALNY
Alnylam Pharmaceuticals, Inc.
$31.61BUSDP/E 41.2
BNTX
BioNTech SE
$29.28BUSD
INSM
Insmed Incorporated
$27.47BUSD
ROIV
Roivant Sciences Ltd. Common Shares
$26.22BUSD
INCY
Incyte Corporation
$25.91BUSDP/E 16.2
GMAB
Genmab A/S
$20.86BUSDP/E 26.3
GMAB
Genmab A/S
$19.26BUSDP/E 26.6
ASND
Ascendis Pharma A/S
$16.61BUSDP/E 19.6
JAZZ
Jazz Pharmaceuticals plc
$16.51BUSDP/E 17.4
BBIO
BridgeBio Pharma, Inc.
$15.93BUSD
EXEL
Exelixis, Inc.
$13.40BUSDP/E 17.0

Key Statistics

Company
Market Cap25.35M $
Enterprise Value-247.62K $
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-34.77M $
Revenue/Share—
Last Price2.540 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees16
CountryUS
SectorHealthcare
IndustryBiotechnology
ISINUS04962H5063
Valuation
P/E (Trailing)—
P/E (Forward)-0.59
PEG—
EV/EBITDA0.01
EV/Revenue—
P/S—
P/B0.96
EPS (TTM)-4.23
EPS (Forward)-4.38
52W Range
1.7005% of range19.35
52W High19.35 USD
52W Low1.700 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-88.35%
ROA-73.03%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-29.76M $
CapEx (TTM)23.00K $
FCF Margin—
FCF Yield-92.04%
Net Debt-26.09M $
Net Debt/EBITDA0.67
Balance Sheet
Debt/Equity—
Current Ratio5.69
Quick Ratio4.79
Book Value/Sh2.689 USD
Cash/Share2.615 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay DateApr 20, 2018
Splits
Last Split1:15
Split DateFeb 2, 2026
Analyst Consensus
Rating1.5 (Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)18.67 USD
Upside (mean)+634.9%
Target Range10.00 USD – 24.00 USD
$10.00+634.9% to mean$24.00
# Analysts3
Ownership
Shares Out.9.98M
Float9.94M
Insiders1.85%
Institutions17.38%
Short Interest
Short Ratio7.2d
Short % Float7.62%
Short % Out.7.62%
Shares Short760.13K
Short (prev mo.)704.02K
Technical
SMA 502.341 (+8.5%)
SMA 2006.122 (-58.5%)
Beta1.25
S&P 52W Chg18.16%
Avg Vol (30d)71.53K
Avg Vol (10d)79.78K
Technical Indicators
RSI (14)52.0
MACD0.0171
MACD Signal-0.0419
MACD Hist.+0.0590
BB Upper2.732 USD
BB Middle2.396 USD
BB Lower2.059 USD
BB Width28.06%
ATR (14)0.1955 USD
Vol Ratio (20d)0.44x